Jack S, Madhivanan K, Ramadesikan S, et al. - Researchers offer the basis for a transformative anti-cancer strategy for bladder cancer, which takes benefit from the unique features of the bladder, and involved the use of an EGF-conjugated anthrax toxin that was internalized and triggered apoptosis in exposed bladder cancer cells after targeting EGFR. This unique agent offered benefits over other EGF-based technologies and other toxin-derivatives. In addition, apoptosis of human (T24), mouse (MB49) and canine (primary) bladder cancer cells could be triggered by it with exposure as short as ≈3 min. One treatment cycle of EGF-toxin caused ~30% average tumor reduction in dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies. Experts concluded that this EGF-anthrax toxin conjugate offers the foundation for novel transformative strategies against bladder cancer owing to high in vitro and in vivo efficiency displayed by it, as well as its fast action (reducing treatment time from hours to minutes) and safety.